INFECTION RISKS AND SURVIVAL OUTCOMES ACROSS RENAL REPLACEMENT THERAPY MODALITIES: A 5-YEAR RETROSPECTIVE STUDY

 

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

 


 

Certificate Background

   

Presented the abstract " "
(Abstract co-author(s):  )

 

 

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
https://storage.unitedwebnetwork.com/files/1099/01dced2f44062d84983eee794a130133.pdf
INFECTION RISKS AND SURVIVAL OUTCOMES ACROSS RENAL REPLACEMENT THERAPY MODALITIES: A 5-YEAR RETROSPECTIVE STUDY

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

  • The title will not be accepted if it exceeds 25 words.
  • Type in CAPITAL LETTERS.
  • Lowercase may be used for abbreviations only, for example, mRNA.
Haruka
Eda
Haruka Eda md.haruka.e@gmail.com Yuuai Medical Center Nephrology Tomigusuku Japan *
Shiho Murai md.haruka.e@gmail.com Yuuai Medical Center Nephrology Tomigusuku Japan -
Kento Murai md.haruka.e@gmail.com Yuuai Medical Center Nephrology Tomigusuku Japan -
Shogo Taira md.haruka.e@gmail.com Yuuai Medical Center Nephrology Tomigusuku Japan -
Shigetomo Terukina md.haruka.e@gmail.com Yuuai Medical Center Nephrology Tomigusuku Japan -
Takayuki Adachi md.haruka.e@gmail.com Yuuai Medical Center Nephrology Tomigusuku Japan -
Tasuku Kikumura md.haruka.e@gmail.com Yuuai Medical Center Nephrology Tomigusuku Japan -
Morikuni Nishihira md.haruka.e@gmail.com Yuuai Medical Center Nephrology Tomigusuku Japan -
 
 
 
 
 
 
 

Japan faces rapid population aging, with the mean age at dialysis initiation rising to 71 years. The leading causes of dialysis initiation are diabetic nephropathy (~40%) and nephrosclerosis (~15%), indicating that over half of patients start dialysis due to arteriosclerotic diseases. Many elderly patients initiate dialysis with multiple comorbidities. Dialysis is costly and often requires frequent hospitalizations, particularly for hemodialysis (HD) patients, affecting both healthcare expenditure and patient quality of life (QOL). Although dialysis patients’ life expectancy is roughly half that of the general population, HD remains the predominant modality. It is uncertain whether patients receive accurate information in renal replacement therapy (RRT) choice consultations. To provide evidence for better life planning, we compared survival rate, infection-related hospitalization, and all-cause hospitalization across RRT modalities.

We retrospectively analyzed 280 patients who initiated preemptive kidney transplantation (PEKT), peritoneal dialysis (PD), or HD at our center between January 1, 2020, and December 31, 2024. Patients were classified by the initial modality, even if they later switched; those who did not transition from emergent to maintenance dialysis were excluded.

Study design: Retrospective observational study

Primary outcomes: Survival, PD-related peritonitis, hospitalization due to pneumonia, bloodstream infection, other infections, or non-infectious causes

Ethical approval: Yuuai Ethics Review Committee (R06R019)

Patient distribution was PEKT 28, PD 56, and HD 196. Median age at initiation was 57, 58, and 71 years, respectively, highlighting the advanced age of HD patients. Survival was highest in PEKT, followed by PD and HD. No patients ≥75 years underwent PEKT; in patients ≥75 years, 5-year survival was ~50% for both PD and HD. Infection-related hospitalization was higher in HD than PD, with PD-related peritonitis at 0.25 patient-years. Overall hospitalization risk was also higher in HD. Differences in infection-related and overall hospitalization between HD and PEKT were minimal.

Although PEKT involves risks such as infections, protocol kidney biopsies, and frequent hospitalizations for stent exchanges, its clear survival benefit outweighs these disadvantages. In patients <75 years, PD offers advantages over HD when considering infection and overall hospitalization risks. For patients ≥75 years, survival is low for both PD and HD; therefore, rather than strongly recommending dialysis initiation, it is essential to discuss treatment decisions with patients while considering infection and hospitalization risks to optimize remaining life quality.

Kewords